Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
Sun Oct 21 00:00:00 GMT-04:00 2018
Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with ...
PDF (193 KB)
Thu Oct 18 00:00:00 GMT-04:00 2018
Daiichi Sankyo Initiates Phase 1 Study of AXL Inhibitor DS-1205 in Patients with EGFR-Mutated Metas ...
PDF (186 KB)
Wed Oct 17 00:00:00 GMT-04:00 2018
Daiichi Sankyo Submits Application in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patient ...
PDF (286 KB)
Wed Oct 03 00:00:00 GMT-04:00 2018
Japan MHLW Grants Orphan Drug Designation to Axicabtagene Ciloleucel for Treatment of Certain Types ...
PDF (101 KB)
Tue Sep 25 00:00:00 GMT-04:00 2018
Daiichi Sankyo Initiates Two Phase 3 Trials of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients ...
PDF (205 KB)
Mon Sep 24 00:00:00 GMT-04:00 2018
Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients wit ...
PDF (269 KB)
Thu Sep 20 00:00:00 GMT-04:00 2018
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KE ...
PDF (197 KB)
Tue Sep 11 00:00:00 GMT-04:00 2018
Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Receives Orphan Drug Designation from Japanese MHLW for ...
PDF (364 KB)
Wed Aug 01 00:00:00 GMT-04:00 2018
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s FLT3 Inhibitor Quizartinib for Rela ...
PDF (365 KB)
Mon Jul 30 00:00:00 GMT-04:00 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug ...
PDF (241 KB)
Showing 11 - 20 of 43 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...